Reference
Rui M, et al. Cost-effectiveness of Osimertinib vs Docetaxel-Bevacizumab in Third-Line Treatment in EGFR T790M Resistance Mutation Advanced Non-Small Cell Lung Cancer in China. Clinical Therapeutics : 4 Oct 2020. Available from: URL: http://doi.org/10.1016/j.clinthera.2020.08.018
Rights and permissions
About this article
Cite this article
Osimertinib cost effective in EGFR T790-mutated NSCLC in China. PharmacoEcon Outcomes News 865, 24 (2020). https://doi.org/10.1007/s40274-020-7248-9
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-020-7248-9